复方丹参滴丸对冠心病患者纤溶系统t-PA、PAI-1含量与活性的调控  

The regulation of complex danshen drop pills on the activity and content of t-PA and PAI-1 in the patients with coronary artery disease

作　　者：唐湘宇[1] 李柏完[1] 王岳林[1] 颜亚平[1] 朱雯霞[2] 杨许平[1] 胡双武[1] 杨向东[2] 

机构地区：[1]南华大学附属第三医院,湖南省衡阳市421900 [2]南华大学心血管病研究所,湖南省衡阳市421900

出　　处：《中国心血管病研究》2008年第2期84-86,共3页Chinese Journal of Cardiovascular Research

基　　金：国家自然科学基金(30200103);湖南省自然科学基金(02JJY4011);教育厅青年基金(02B039)

摘　　要：目的观察复方丹参滴丸对冠心病患者内源性纤溶活性及血管内皮功能的影响,探讨其作用机制。方法冠心病患者78例,随机分为对照组和复方丹参滴丸组。对照组采用常规治疗;复方丹参滴丸组在常规治疗基础上加用复方丹参滴丸每次10粒,每日3次。两组用药时间均为4周。比较治疗前后血浆组织型纤溶酶原激活剂(t-PA)、纤溶酶原激活剂抑制因子-1(PAI-1)活性及浓度。结果复方丹参滴丸治疗4周后,患者血浆PAI-1活性及浓度下降(P<0.05),t-PA活性及浓度含量升高(P<0.05),与治疗前比较差异有统计学意义;常规治疗组治疗前后t-PA和PAI-1活性差异无统计学意义。结论复方丹参滴丸可有效地调控改善冠心病患者内源性纤溶活性及血管内皮功能。Objective To observe the effect of complex danshen drop pills （CDDP） on the endogenous fibrinolytic activity and vascular endothelial function in the patients with coronary artery disease （CAD）, and to study the mechnisms. Methods 78 patients with CAD were randomly divided into control group and CDDP group. Conventional therapy were adopted in the control group. The CDDP group adopted conventional therapy and CDDP that the patients took 10 pills each time and three times a day. The activity and content of plasma Tissue type plasminogen activator（t-PA ）and Plasminogen activator inhibitor （PAI-1） were detected before treatment and after treatment for 4 weeks.Results After treatment with C DDP for 4 weeks, the activity and content of plasma t- PA were significantly increased and the activity and content of plasma PAI-1 were significantly decreased in the CDDP group. There were not the significant change that happened in the control group. Conclusion The experimental results suggested that CDDP could effectively regulated and ameliorated vascular endothelial function and plasminogen activity in patients with CAD.

关 键 词：复方丹参滴丸 冠状动脉疾病 组织型纤溶酶原激活物 纤溶酶原灭活剂 

分 类 号：R541.4[医药卫生—心血管疾病]